ArticleChinese journal of cancer2016

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.

Xue-Lian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.